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Abstract
Facing metastasis is the most pressing challenge of cancer research. In this review, we discuss
recent advances in understanding phenotypic plasticity of cancer cells, highlighting the kinetics
of cancer stem cell and the role of the epithelial mesenchymal transition for metastasis. It appears
that the tumor micro-environment plays a crucial role in triggering phenotypic transitions, as we
illustrate discussing the challenges posed by macrophages and cancer associated fibroblasts. To
disentangle the complexity of environmentally induced phenotypic transitions, there is a grow-
ing need for novel advanced algorithms as those proposed in our recent work combining single
cell data analysis and numerical simulations of gene regulatory networks. We conclude dis-
cussing recent developments in artificial intelligence and its applications to personalized cancer
treatment.
Keywords: , cancer stem cells, phenotypic switching, metastasis, precision medicine
Cancer stem cells, phenotypic switching and metastasis
Cancer stem cells (CSCs) have been defined as cells with the capability of self-renewing,
generating an heterogeneous population within the tumor [1]. According to this view, tumors
expand in a hierarchical way, with CSC at the apex of the tree. The other model of tumor growth
is the stochastic one, postulating that cancer cells are heterogeneous but are all able to sustain
tumor growth [2]. There was evidence in support of both hypotheses, but according to the recent
literature the two models are actually not in contrast. Indeed, there is a growing support to the
idea that the cancer cell population is dynamic, with cancer cells (CCs) that are able to revert
into CSCs. This general phenomenon is called phenotypic switching.
A brief summary of the most relevant papers showing a phenotypic switching in tumor cells are
discussed below. In 2011, a paper pointed out the possibility that non-CSCs breast cancer cells
can revert to a stem cell like state even in the absence of mutations [3]. In melanoma, a small
population of CSC-like histone demethylase 5B (JARID1B) positive cells has been shown to be
Preprint submitted to Seminars in Cancer Biology June 28, 2018
Page 2 of 13
Ac
ce
pte
d M
an
us
cri
pt
dynamically regulated in a way that differs from the standard hierarchical CSC model [4]. Micro-
environmental factors, such as transforming groth factor beta (TGFbeta), are found to enhance
the rate of switch from non-CSC cells to the CSC state [5]. In this connection, ATP Binding
Cassette Subfamily G Member 2 (ABCG2) negative cells isolated from human melanoma biop-
sies express again this marker after few passages in vitro [6]. Instead of a switch to a CSC state
driven by genetic mutations, recent papers suggest a crucial role of epigenetic factors modulated
by the environment in human intestine and melanoma cells [3, 7, 8, 9, 10, 11, 12, 13]. Moreover,
the possibility to limit stemness by modifying the microenvironments has also been shown in a
zebrafish-specific melanoma cell line (ZMEL1) [13, 14]. Our group contributed to this specific
goal showing the critical role of the microenvironment on specific target of stemness such as
Wingless-type integration (Wnt) and Phosphoinositide 3-kinase (PI3K)-pathways by miRNAs in
human melanoma [12]. In fact, we showed that cancer cells can switch into CSCs thanks to
a complex miRNA network which in turns regulates crucial pathways of stemness such as Wnt
and PI3K [12]. On the other side, we demonstrated that the miRNA network is activated when
the CSC population is reduced below a threshold, implying that cancer cells are sensitive to the
number of CSCs in the bulk [12]. This is a typical feature of normal stem cells which have to
maintain their number exactly constant due to space limitations in the niche. Recently in stem
cells, the spatial-dependent activation of Wnt signaling was shown to dictate differentiation and
spatial confinement in the niche [15] and to regulate the number of stem cells [16].
Based on those studies, phenotypic switching emerges as a tightly regulated process that is
dependent on the numbers of CSCs in the bulk, implying the presence of a crosstalk between
the cells. Taken together, this evidence clearly shows that a scenario based only on a stochastic
process is too simple for tumor development. Cancer cells show a high degree of plasticity and
there is an equilibrium between CSCs and their more differentiated progeny. One of the most
important consequences of phenotypic switching is related to metastasis. The metastatic process
is usually interpreted based on the idea that each metastasis arises from the clonal growth of a
single tumor cell that has detached from tumor mass and migrated elsewhere, however the recent
evidence showed that this view has to be revised [17]. For example the circulating tumor cells
(CTCs) have been found to move as clusters of cells in the blood of patients [18]. Therefore
the classical view is that of a continuous biological process consisting in a sequence of distinct
steps: from local invasion to intravasation, from extravasation to colonization. According to
this view, it is critical to understand the complex array of biological factors determining the
progression from primary malignancy to overt metastasis. When and why a tumor becomes able
to relapse is, however, still unknown. According to the phenotypic switching view, migration
to a distant site could be done by CSCs but also by CCs which could then switch and seed new
metastasis by undergoing an epithelial-mesenchymal transition (EMT). To switch the phenotype,
the environment might play a critical role as discussed recently [17]. Moreover, according to
the literature, CSCs migration appears unlikely since they typically represent a small fraction of
the cancer cell population. In light of this evidence, instead of targeting CCs or CSCs, it could
be more promising to target the niche to overcome cellular resistance and prevent metastasis (see
Fig. 1).
Plasticity in cancer cells: the epithelial mesenchymal transition
The EMT, controlled by a numbers of transcription factors [19], is associated with the loss of
cell-cell adhesion and the gain of invasive traits and is therefore a hallmark of plasticity within
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a stem cell population and appears particularly relevant for tumors. Almost 80% of human ma-
lignancies which origin from epithelial tissues express mesenchymal markers, being usually as-
sociated with a more aggressive phenotype [19, 20, 21, 22]. More recently, interesting evidence
shows that the EMT is a multiple process where cells express a mix of markers, characteristic
of both epithelial and mesenchymal cells [23, 24, 25]. Hence, the rigid distinction between ep-
ithelial and mesenchymal phenotype is becoming more fuzzy: Cancer cells can acquire hybrid
phenotypes, combining invasive capabilities with intracellular adhesion [24, 25]. It turns out
that hybrid cells are extremely aggressive and associated to a poor patient outcome [26, 27].
In a recent paper, we have investigated this aspect using a combination of numerical simula-
tions of a Boolean network model of the EMT pathways and the analysis of bulk and single cell
gene expression data [28]. Interestingly, we showed that the EMT involves the transit through a
multitude of meta-stable states, corresponding to highly aggressive hybrid cells that can easily
switch under external and internal perturbations [28]. Our study allowed to reconstruct the to-
pography of the phenotypic landscape, as originally envisaged in general terms by Waddington
more than sixty years ago [29] and rationalized as the possible attractors of the relevant gene
regulatory network [30, 31, 32, 33, 34, 35, 36, 37] In contrast to the smooth landscape depicted
by Waddington, the landscape emerging from the kinetics of the EMT regulatory network is ex-
tremely complex, with a hierarchically organized set of valleys and mountains corresponding to
an impressive number of cell phenotypes separating epithelial and mesenchymal states (Fig. 2)
[28]. Hence, phenotypic switching can take multiple paths and produce a variety of outcomes
corresponding to the astonishing the complexity of a cancer cell population. Furthermore, the
large number of states expressed by the network confirms that we should abandon the rigid dis-
tinction between epithelial or mesenchymal cells. We should think instead about a continuum of
possible cell phenotypes with varying degrees of plasticity. In light of these findings, metastasis
could be due to one of these CCs with hybrid phenotype that can easily migrate and switch in
the right environment. According to this complex landscape, Wicha’s group showed that CSCs
mantain plasticity to transition between mesenchymal-like and epithelial-like stated in response
to the tumor microenvironment [38]. There are also consequences for the development of new
therapeutic strategies based on the possibility to target essential mechanisms controlling the EMT
through the microenvironment [39].
Another interesting aspect that might be linked to EMT is the presence of dormant tumor cells.
It has been shown in the last decade that disseminated cancer cells might display slow growth
to adapt to the host microenvironment for the metastatic expansion [40, 41, 42, 43, 44]. There
is a tropism specific to each organ that can help the metastatic process and the expansion of the
tumor [40, 41, 42, 43, 44]. CTCs or disseminated tumor cells (DTCs) can stay dormant through
inhibition of cell proliferation and activation of cell survival pathways [45, 46]. These cells are
undetectable for long period and might be the reason for the relapse of the tumor [47, 48, 49,
50]. It is remarkable that DTCs have also been observed in primary tumors undergoing EMT to
develop migratory and invasive phenotypes [50, 51].
As shown in Fig. 3, in an epithelial primary tumor, some cancer cells, either CCs or CSCs,
could switch to a mesenchymal phenotype, enter the nearest vessel, reach a secondary site
through the circulation, extravasate and become dormant. When the environment is permis-
sive, these cells or part of them could switch back to an epithelial phenotype and grow (Fig.3).
The strict relationship between the tumor cells and the microenvironment seems to be a crit-
ical factor for the reactivation of dormant metastatic cells. The transition to the mesenchy-
mal phenotype is important for the formation of micrometastasis. The presence therefore of a
favourable microenvironment is an essential condition during metastasis development. Further-
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more, metastatic niche formation needs the involvement of inflammation, immunosuppression,
angiogenesis/vascular permeability, organotropism, lymphoangiogenesis and cellular reprogram-
ming [52]. In this connection, macrophages have been shown to be critical, in particular a subset
of macrophages (Tumor associated macrophages) [53, 54, 55, 56]. The reactivation of the dor-
mant cells appears to involve many factors including TGFbeta that support the production of
periostin from stromal fibroblasts and endothelial cells in the vascular area [57, 58]. Finally, the
possibility to neutralize dormant cells acting through the niche can be an important support to
chemotherapy or help maintain a dormant state.
Cancer niche: new challenges
Tumor cells require nutrients and signals from the surrounding microenvironment which also
regulates a dynamic balance between CSCs and CCs. The tumor niche comprises different
types of cells in addition to a non-cellular component (cytokines, growth factors etc), mainly
cancer-associated fibroblasts (CAF) and macrophages. Macrophages are present in the tumor
microenvironment together with immune cells, endothelial cells, fibroblasts and mesenchymal
stromal/stem cells and communicate with the tumor. They can drive different states of activa-
tion in response to different microenvironment: M1 (the killing phenotype) and M2 (the heal-
ing phenotype). In fact, while M1 was shown to help a pro-inflammatory environment, M2
is an anti-inflammatory one. In recent years, however, many papers showed that macrophages
polarize in a more broad spectrum of phenotypes involved in various immunoregulatory disor-
ders. Macrophages play an important role for the control and clearance of infections, removal
of debrits and dead cells, promoting tissue repair and would healing. However they can also
be involved in inflammation and tissue damage helping the tumor to grow and disseminate. In
particular, M2 cells help the tumor while M1 exhert an anti-tumor activity [59]. These cells
are incredibly plastic and can switch from one phenotype to the other [60, 61]. Polarization of
macrophages to a specific phenotype is due to local cytokines [61].
According to the literature, tumor associated macrophages (TAMs) are the major infiltrating
leukocytes of the tumor micro-environment [62]. They have usually a M2-like phenotype and
an immunosuppressive activity, producing growth factors for the tumor cells [62]. TAMs also
promote dissemination of tumor cells enhancing angiogenesis and matrix degradation, suppress-
ing Th1 immne ativity [63]. In particular, the production of matrix metalloproteases (MMP),
osteonectin and cathepsins by TAMs helps tumor cells to escape from the original mass and
invade the surrounding tissue. In general, there is ample evidence in breast and ovarian can-
cer showing that TAM infiltration is correlated to a poor patient survival [63]. On the other
hand, direct targeting of TAMs or re-polirization toward M1 phenotype in the microenvironment
seems to represent an attractive way to affect the tumor development towards a more aggressive
phenotype. Interestingly, recent studies showed that TAMs are able to orchestrate EMT [64]
in pancreatic cells. Furthermore, TAMs promote CSC-like properties via TGF-beta1, inducing
EMT in hepatocellular carcinoma [65]. These studies and others suggest that TAMs play a crit-
ical role in the development of an environment that helps the premetastatic niche, by reteining
circulating cells and helping their growth [54]. There is evidence in the literature suggesting
that TAMs are associated with CSCs [66, 67]. All together, these data strongly support the idea
to target TAMs in order to destabilize the tumor microenvironment [68].
Cancer-associated fibroblasts (CAF) are major components of the stroma of tumors. Fibrob-
lasts can show an altered phenotype characterized by an increased expression of markers such
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as alpha-smooth muscle actin (a-SMA) and fibroblast activation protein (FAP) and also an in-
creased expression of extracellular matrix proteins such as collagen type I [69]. Both migration
and invasion are supported by CAF-secreted factors (i.e TGFbeta) helping the transition from
epithelial to mesenchymal phenotype of the tumor [70]. CAFs are shown to play a critical role
in the organization of the niche which helps tumor to invade. In fact, considering that one of
the most important function of the fibroblasts is to deposit and assembly the extracellular matrix,
CAFs exhibit an abnormal activity in terms of extracellular matrix regulation, releasing high lev-
els of fibronectin and type I collagen as well as high level of expression and activation of MMPs
[71]. The effect of CAFs is either on the tumor cells and on the stroma. CAFs were also shown
to modulate the tumor vasculature, a critical element to refurbish the tumor cells with nutrients
and oxygen and removing waste products. Due to the excessive production of these factors,
the vessels are abnormal with structural instability due to defective coverage with pericytes and
basement membrane [72]. Therefore CSFs can modulate the vasculature through the release of
for example VEGF, CXCL12 and MMPs, they can modulate the immune systems (TGFbeta),
the extracellular matrix and the same cancer cells. It is thereby quite clear that the possibility to
target these cells in the tumor niche could destabilize the tumor, help maintaining it a quiescent
state or lead cells to death. Hypoxia is a typical feature of tumors and has been shown to control
the remodelling of extracellular matrix [73] but also affect CAFs [74].
Targeting the niche where tumor cells live seem to be promising because of the heterogeneity
of the tumor population and the difficulty to target them. CAFs and TAMs seem to be particular
relevant for the development of the tumor toward a more aggressive phenotype.
Artificial intelligence, personalized medicine and real world data
Two great revolutions happened in recent years: the possibility to store a great amount of data
and the growing speed of computers which are able to perform more operations in a shorter time.
These two simple technological improvements are already able to speed up many human daily
functions and also have an impact on medicine, including cancer. Computer algorithms and data
analysis tools are behind several consumer services from travel agencies to recommendation sys-
tems for books, movies and music. There is an industrial revolution that started first in the society
and in the relationship between people (driven by commonly used social media) and has finally
reached medicine, where it is changing our approach to understand and fight diseases. Data sets
grow rapidly in part because they are increasingly gathered by cheap and numerous information-
sensing internet devices such as mobile phones. These technologies are entering in medicine
too, speeding up the collection and the amount of data. For instance, epidemic surveillance can
now rely on large but low quality data from social media to complement traditional public health
approaches. Algorithms for automatic image analysis are rapidly outperforming trained humans
in the classification of certain types of cancers [75].
The classical biological approach to study cancer is based on experiments carried out in a wet
laboratory, sharing of the results with the scientific community through scientific publications
and finally dissemination at conferences and seminars. Throughout this process, the research
community is storing a huge amount of biological data (from genomes and transcriptomes to
bioptic samples) related to tumors. Thanks to recent improvements in computer power and al-
gorithmic performance, we can try to extract useful information from all these data. It is well
known that artificial intelligence (AI) works very well on image recognition and indeed this
has been its first application on biology. As mentioned above, skin cancer has been recently
classified using AI, showing excellent results when compared with traditional analysis [75]. In
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another recent paper, the authors used deep learning based tissue analysis to predict the outcome
for colorectal cancer [76] . Other possible applications are, however, still under investigation
and require additional effort. One important example is the idea to connect genomic data to the
disease phenotype through a maching learning or a deep learning approach. Earlier approaches
to predict clinical outcome in cancer patients using machine learning on selected gene expression
data have been shown, however, to suffer from serious shortcomings [77]. The main reason is
that the number of available samples was too small to draw statistically firm and biologically
meaningful conclusions from the data [77].
Hence, the most pressing issue in the field is to develop computational tools that are able
to integrate and analyze data coming from different sources and, at the same time and more
importantly, to ask the right questions to the data. Our group started about ten years ago an
interdisciplinary program combining wet laboratory experiments with computational approaches
and tools stemming from the physics of complex systems (for a comprehensive review see [78]).
At that time, few biologists understood the great power of sharing expertise between medicine,
mathematics and physics. Now we have developed powerful tools which pave the way to the
development of a personalized medicine based on artificial intelligence [17] . Combining data
into large sets allowed us to better explore hidden but relevant information that would not appear
when analyzing small data sets because of the inevitable background noise. As discussed in
a recent article [79], big data analysis in biology is difficult and one of the main sources of
difficulty is related to the fact that data shared within the scientific community are not uniform
in their format. Our group used an artificial intelligence approach to address the question of the
search for common factors shared in obesity and breast cancer, motivated by the high frequency
of obese females developing breast cancer [80]. To reach this goal, the possibility to integrate
all the data available in the literature was crucial, since each study usually reports results from
just few cases. We need a large number of cases to break the curse of dimensionality, inevitable
in the search for a signature among 20000 genes using a 20 samples. We solved the problem by
algorithms combining singular value decomposition and pathways deregulation analysis [80]. In
this way, we identified a signature of 38 highly significant genes that are differentially expressed
in obese subjects and a set of pathways that are shared between obesity and breast cancer. Finally,
we showed that this gene expression signature is induced by obesity rather than emerging from
a genetic fingerprint, by analyzing a large cohort of monozygotic twins [81].
Pharmaceutical companies are also changing their approach and try to develop new drugs
using machine learning [82] but they are also starting to appreciate the potentially interesting
information hidden in already available data. Real-world data (RWD), in the definition of the
International Society for Pharmacoeconomics and Outcome Research, include all the data going
beyond what is usually collected in phase III clinical trials and also any outcome that is not
purely interventional [83]. Many innovative aspects are included in RWD. First, health-care
decision makers are now starting to devise policies based on integrated evidence coming from a
multitude of sources. This is important because it can provide information that goes beyond what
has been obtained in the trial, such as the way how a particular drug works in populations not
covered by the trial [84]. Secondly, RWD include information about the actual treatment patients
received, also including co-morbidity, so that RWD can be used to study the effect of multiple
interventions. The main problem now is the availability of good quality RWD and sufficiently
representative databases, since in many countries databases are incomplete.
The possibility to devise a personalized medicine could be achieved, in our opinion, by the
convergence between the development of new algorithmic strategies to investigate already avail-
able biological data in genomics, transcriptomics and images combined with the acquisition of
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new information through RWD. Beside algorithms needed to extract and visualize information
from data, we also need predictive models to estimate the probability of therapeutic success of
each strategy.
Conclusions: Precision medicine and tumor plasticity
The idea that tumors are highly heterogeneous is already mainstream in the field of cancer
biology. The plasticity of tumor cells driven by the microenvironment, that under the right con-
ditions induces cells to switch and seed new metastasis, is becoming an additional hallmark of
cancer. Disentangling the evolution of single cells inside the tumor opens a new interesting area
to understand better the complex relationship between tumor cells and the environment. Our new
understanding of tumor plasticity and the important role of the microenvironment in controlling
this process provides concrete answers to the quest for precision medicine [28]. To this end,
we need to combine innovative algorithms for single cells gene expression analysis with predic-
tive computational models driving the therapeutic intervention. We have discussed in depth the
important role played by the microenvironment to affect the state of tumor cells (EMT/MET),
therefore one promising aspect is to target of the microenvironmental instead of the tumor cells
to control their plasticity.
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Figure captions
Figure 1: Phenotypic switching of CSCs. Phenotypic transitions between CCs and CSCs are controlled by a large
cohort of environmental factors..
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Figure 2: Topography of the epithelial mesenchymal transitions. Epithelial and mesenchymal phenotypes are ar-
ranged in a complex hierarchical landscape with multiple possible transition. A multitude of hybrid states reside at the
top of the landscape and owing to their reduced stability can rapidly change into a different phenotype.
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Figure 3: Phenotypic transitions and metastasis. Epithelial cancer cells, either CCs or CSCs, can acquire a mesenchy-
mal phenotype, intravasate, then extravasate at a distant site and become dormant. Under favorable conditions, dormant
cells can switch back to the epithelial state and grow.
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